Sorry, you need to enable JavaScript to visit this website.

A Study of Two Inotuzumab Ozogamicin (InO) Doses in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Transplant Eligible Patients

A Study of Two Inotuzumab Ozogamicin (InO) Doses in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Transplant Eligible Patients. A Phase 4, Open-Label, Randomized Study of Two Inotuzumab Ozogamicin Dose Levels
in Adult Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Eligible for Hematopoietic Stem Cell Transplantation and Who Have Risk Factor(s) for Veno-Occlusive Disease.

Category & Conditions: Cancer
Medicine: BESPONSA™ FOR INJECTION(INOTUZUMAB OZOGAMICIN)
ClinicalTrials.gov Identifier (NCT): NCT03677596
Protocol ID: B1931030
PrintDownload
Open Plain Language Summary Result: Click here